BRIDGEWATER, N.J., Feb. 26 /PRNewswire-FirstCall/ -- Sanofi-aventis announced today that the U.S. Food and Drug Administration (FDA) approved Apidra(R) SoloSTAR(R ...

Basaglar (insulin glargine) and Lantus (insulin glargine) are brand-name prescription medications. They’re approved by the Food and Drug Administration (FDA) to: improve blood sugar levels in adults ...

HERTFORDSHIRE, England and PITTSBURGH, May 29, 2020 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced that the U.S. Patent and Trademark Appeal Board (PTAB) has ruled in favor of Mylan in inter ...

TRENTON, N.J. — A less-expensive version of the world’s top-selling insulin, Sanofi’s Lantus, could go on sale in the U.S. late next year. The French drugmaker said Monday it settled a lawsuit over ...

NEW YORK Sanofi-aventis’ SoloSTAR insulin pen has some serious competition. Two independent studies in Germany and Japan have found that Novo Nordisk’s FlexPen was more accurate in delivering insulin ...

FILE PHOTO: The logo of Sanofi is pictured during the Viva Tech start-up and technology summit in Paris, France, May 25, 2018. REUTERS/Charles Platiau (Reuters) - U.S. generics drugmaker Mylan said on ...

Sanofi Aventis launched a Lantus-branded “diabetes awareness campaign” featuring Paul and Mira Sorvino. The father-daughter acting duo, he of Goodfellas fame and she of Mighty Aphrodite, feature in ...

Sanofi-Aventis launched a Lantus-branded “diabetes awareness campaign” featuring Paul and Mira Sorvino. The father-daughter acting duo, he of Goodfellas fame and she of Mighty Aphrodite, feature in ...

PARIS, Feb. 25, 2015 /PRNewswire-USNewswire/ -- Sanofi announced today that the U.S. Food and Drug Administration (FDA) approved Toujeo® (insulin glargine [rDNA origin] injection, 300 U/mL), a ...

Sanofi, rival drugmakers Lilly, Boehringer settle suit allowing rival to Lantus insulin in US This product image provided by Sanofi shows Lantus SoloStar, the French drugmaker's once-daily insulin in ...

(Reuters) - U.S. generics drugmaker Mylan said on Thursday that the United States Patent and Trademark Office had rejected Sanofi's infringement claims relating to insulin drug Lantus. Sanofi is ...